SelenBio™? Marks One Year Since Launch of FDA-Approved Dental Breakthrough
SelenBio™? Marks One Year Since Launch of FDA-Approved Dental Breakthrough

It's been one year since SelenBio, Inc.™?, a Texas-based biotechnology company, launched DenteShield™?, a dental product proven to inhibit bacteria colonization responsible for plaque, decay, white spot lesions and...

New Study Indicates Payments Impact Site Sustainability, Patient Experience and Overall Clinical Trial Success
New Study Indicates Payments Impact Site Sustainability, Patient Experience and Overall Clinical Trial Success

Greenphire, the global leader in financial software for clinical trials, and the Society for Clinical Research Sites (SCRS) today announced the findings of their new study, Financial Barriers to Site Sustainability,...

The Lancet Publishes Phase 3 Results Demonstrating Efficacy, Safety and Tolerability of SUBLOCADE™ (Buprenorphine Extended-Release) Injection for Subcutaneous Use (CIII) in Patients with Moderate to Severe Opioid Use Disorder (OUD)
The Lancet Publishes Phase 3 Results Demonstrating Efficacy, Safety and Tolerability of SUBLOCADE™ (Buprenorphine Extended-Release) Injection for Subcutaneous Use (CIII) in Patients with Moderate to Severe Opioid Use Disorder (OUD)

Indivior PLC (LON: INDV) today announced that data from its pivotal phase 3 clinical trial evaluating the efficacy, safety and tolerability of SUBLOCADETM (buprenorphine extended-release) injection for subcutaneous use...

Alkermes and Clovis Oncology Initiate Research Collaboration to Explore Combination Cancer Therapies
Alkermes and Clovis Oncology Initiate Research Collaboration to Explore Combination Cancer Therapies

Alkermes plc (Nasdaq: ALKS) and Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that the companies have entered into a research collaboration to evaluate ALKS 4230, Alkermes' investigational engineered...

Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain
Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain

Pfizer Inc. (NYSE: PFE) and Eli Lilly and Company (NYSE: LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab in patients with moderate-to-severe chronic low back pain (CLBP). In the...

Widow Support Groups Continue to See Significant Growth: United in Assignment, LLC Provides Grief Support Programs for Healing & Life Design After Loss of a Spouse
Widow Support Groups Continue to See Significant Growth: United in Assignment, LLC Provides Grief Support Programs for Healing & Life Design After Loss of a Spouse

According to a recent study by Columbia University, more than 40% of surviving spouses will struggle to adjust into their previous work and daily routines; and only 26% of widows return to their pre-loss level of life...

Dutch University Hospital Chooses Sectra for Digitizing Pathology for Primary Diagnostics
Dutch University Hospital Chooses Sectra for Digitizing Pathology for Primary Diagnostics

International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has received an order from Radboud University Medical Center (Radboudumc) in the Netherlands for its IT solution for digital pathology. The...

Confirm BioSciences At-Home Drug Detection Tool HairConfirm® to Roll Out at Major National Retailers Starting February 2019
Confirm BioSciences At-Home Drug Detection Tool HairConfirm® to Roll Out at Major National Retailers Starting February 2019

Confirm BioSciences, maker of high-quality diagnostic testing and health & wellness solutions for both the corporate community and individual consumers, today announced its entry into retail distribution for its...

The Kroger Family of Pharmacies Partners with MarkeTouch Media to Implement Medication Synchronization Program
The Kroger Family of Pharmacies Partners with MarkeTouch Media to Implement Medication Synchronization Program

The Kroger Family of Pharmacies has worked with Houston-based MarkeTouch Media to apply an innovative and unique method of assisting patients through medication synchronization ("MedSync"). The solution leverages a central...

Chipscreen Biosciences Announces a Collaboration with Innovent to Evaluate Chidamide and the Combination of Sintilimab, Anti-VEGF Monoclonal Antibody IBI305 in Colorectal Cancer patients
Chipscreen Biosciences Announces a Collaboration with Innovent to Evaluate Chidamide and the Combination of Sintilimab, Anti-VEGF Monoclonal Antibody IBI305 in Colorectal Cancer patients

Chipscreen Biosciences, a leading integrated Chinese biotech company specialized in discovery and development of novel small molecule pharmaceuticals with a primary focus in oncology, metabolic disease, and autoimmune...

UK-based Biotech Company, AKLRD, Rewarded for Unique Approach to Drug Development by UK Government's Innovation Body
UK-based Biotech Company, AKLRD, Rewarded for Unique Approach to Drug Development by UK Government's Innovation Body

AKL Research and Development (AKLRD) today announces its investigational medicine for osteoarthritis (OA) has been awarded a prestigious grant from Innovate UK, the leading government innovation agency.

Innovent Announces a Collaboration with Chipscreen Biosciences to Evaluate the Combination Therapy in Colorectal Cancer Patients
Innovent Announces a Collaboration with Chipscreen Biosciences to Evaluate the Combination Therapy in Colorectal Cancer Patients

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality innovative medicines for the treatment of oncology, autoimmune and...

New Early Breast Cancer Drug To Be Made Available In Singapore Via Special Access Program
New Early Breast Cancer Drug To Be Made Available In Singapore Via Special Access Program

A NEW breast cancer drug shown to significantly reduce the risk of cancer recurrence is being made available to women in Singapore from today via a Special Access Program.

Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine
Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine

JAVELIN Renal 101 shows significant improvement in progression-free survival with a hazard ratio of 0.69 in patients regardless of PD-L1 expression US FDA has granted Priority Review to BAVENCIO plus INLYTA for patients...

Statement from ABC President John M. Fontaine, MD, on the 2018 ACC/AHA Guideline on Management of Blood Cholesterol
Statement from ABC President John M. Fontaine, MD, on the 2018 ACC/AHA Guideline on Management of Blood Cholesterol

The Association of Black Cardiologists, Inc. is a cosigner of the recently published 2018 ACC/AHA Guideline on Management of Blood Cholesterol, a document that was carefully crafted by the writing committee and experts in...

Providers Use Therap's Disability Software to Generate Comprehensive Reports for Audits, Compliance and Quality Assurance
Providers Use Therap's Disability Software to Generate Comprehensive Reports for Audits, Compliance and Quality Assurance

Therap's electronic health record and documentation system is the leading software globally and within the United States to providers supporting individuals with intellectual and developmental disabilities.  Its...

ControlRad Adds Industry-Veteran Chris Fair to its Executive Management Team
ControlRad Adds Industry-Veteran Chris Fair to its Executive Management Team

ControlRad, LLC, a privately-held medical technology company, focused on dramatically reducing the amount of radiation exposure during fluoroscopically guided procedures, is pleased to announce that Chris Fair has joined...

Clinical Data Presented from PIVOT-02 Study of Bempegaldesleukin (NKTR-214) with Nivolumab in Metastatic Urothelial Carcinoma Patients at the 2019 ASCO Genitourinary Cancers Symposium
Clinical Data Presented from PIVOT-02 Study of Bempegaldesleukin (NKTR-214) with Nivolumab in Metastatic Urothelial Carcinoma Patients at the 2019 ASCO Genitourinary Cancers Symposium

Nektar Therapeutics (Nasdaq: NKTR) announced today a presentation of new clinical data for bempegaldesleukin1 (NKTR-214) in combination with nivolumab in patients with first-line (1L) advanced or metastatic urothelial...

Bayer to obtain full rights to global development and commercialization of oncology compounds Vitrakvi® (larotrectinib) and BAY 2731954 (LOXO-195)
Bayer to obtain full rights to global development and commercialization of oncology compounds Vitrakvi® (larotrectinib) and BAY 2731954 (LOXO-195)

Bayer has exercised its option, under a change-in-control clause in the collaboration agreement with Loxo Oncology, to obtain the exclusive licensing rights for the global development and commercialization, for Vitrakvi®...

Avapritinib receives Phase III clinical trial approval for GIST in China
Avapritinib receives Phase III clinical trial approval for GIST in China

CStone Pharmaceuticals ("CStone") today announced that the National Medical Products Administration (NMPA) recently approved a Phase III clinical trial in China for its partnered drug candidate avapritinib as a third-line...

Arp, Big Sandy, Odessa Schools Join Superior HealthPlan To Celebrate National No One Eats Alone Day
Arp, Big Sandy, Odessa Schools Join Superior HealthPlan To Celebrate National No One Eats Alone Day

A positive prevention initiative designed to promote inclusion in middle schools was celebrated earlier this month by Big Sandy Junior High in Big Sandy, TX, Arp Junior High in Arp, TX and at Bowie Middle School in Odessa.

Glenmark to spin off its innovation business into a new company in the US
Glenmark to spin off its innovation business into a new company in the US

Glenmark Pharmaceuticals Ltd, a research-led integrated global pharmaceutical company, today announced that its Board of Directors has given an in-principle approval to spin off the innovation business into a new company...

Janssen Announces Preliminary Results from Phase 2 GALAHAD Study in Adults with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Pathway Defects (DRD)
Janssen Announces Preliminary Results from Phase 2 GALAHAD Study in Adults with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Pathway Defects (DRD)

The Janssen Pharmaceutical Companies of Johnson & Johnson will present today at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) early results from the ongoing Phase 2 GALAHAD study...

Lua Technologies, A Subsidiary Of Life Biosciences, Rated As The Leading Post-Acute Secure Messaging Solution By KLAS Research
Lua Technologies, A Subsidiary Of Life Biosciences, Rated As The Leading Post-Acute Secure Messaging Solution By KLAS Research

Lua Technologies, a subsidiary of Life Biosciences Inc, has been ranked the highest scoring post-acute secure messaging solution in the 2018 Secure Communication Decision Insights Report from KLAS Research. Lua received...

A Retrospective Study of Medicare Claim Data Shows Patients Treated with Voraxaze® had Shorter Hospitalizations and Lower Mortality
A Retrospective Study of Medicare Claim Data Shows Patients Treated with Voraxaze® had Shorter Hospitalizations and Lower Mortality

BTG plc (LSE: BTG), the global healthcare company, today announced the publication of data showing that cancer patients with presumed methotrexate toxicity treated with Voraxaze® (glucarpidase) had shorter hospital stays,...

Rhode Island Headlines 

Massachusetts Headlines 

National